title: Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
abstract: The aim of this study was to evaluate the medium-term effects of the selective AT1-blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT,-blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.
authors.affiliation: Department of Second Cardiology, Medical School, Aristotle University of Thessaloniki, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Kotridis
authors.forename: Basile
authors.initials: B
authors.lastname: Kokkas
authors.forename: Michalis
authors.initials: M
authors.lastname: Karamouzis
authors.forename: George
authors.initials: G
authors.lastname: Sakadamis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kanonidis
authors.forename: George
authors.initials: G
authors.lastname: Dadous
authors.forename: Chrisoula
authors.initials: C
authors.lastname: Karantona
authors.forename: Olga
authors.initials: O
authors.lastname: Gouli
authors.forename: Joshef
authors.initials: J
authors.lastname: Karadoumanis
authors.forename: Pavlos C
authors.initials: PC
authors.lastname: Papadopoulos
authors.forename: Constantine L
authors.initials: CL
authors.lastname: Papadopoulos
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D009320:Atrial Natriuretic Factor; D000077405:Irbesartan